Oakworth Capital’s TG Therapeutics TGTX Stock Holding History

Oakworth Capital’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.5K	Hold	500	–	–	﹤0.01%	559
2026 Q1	$16.6K	Hold	500	–	–	﹤0.01%	600
2025 Q4	$14.9K	Hold	500	–	–	﹤0.01%	609
2025 Q3	$18.1K	Hold	500	–	–	﹤0.01%	568
2025 Q2	$18K	Hold	500	–	–	﹤0.01%	454
2025 Q1	$19.7K	Hold	500	–	–	﹤0.01%	457
2024 Q4	$15.1K	Hold	500	–	–	﹤0.01%	485
2024 Q3	$11.7K	Hold	500	–	–	﹤0.01%	495
2024 Q2	$8.89K	Hold	500	–	–	﹤0.01%	502
2024 Q1	$7.61K	Hold	500	–	–	﹤0.01%	492
2023 Q4	$8.54K	Buy	+500	New	+$5.81K	﹤0.01%	493

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Oakworth Capital's TGTX Position: Q2 2026 in Review

Oakworth Capital held its TG Therapeutics (TGTX) position steady in Q2 2026 at 500 shares worth $27.5K. The position accounts for ﹤0.01% of the portfolio, ranked #559.

Oakworth Capital first reported a position in TGTX in Q4 2023 and has held it in 11 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Oakworth Capital held 500 shares of TG Therapeutics worth $27.5K as of Q2 2026.
Oakworth Capital left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up ﹤0.01% of Oakworth Capital's portfolio in Q2 2026, its #559 holding.
Oakworth Capital first reported a position in TG Therapeutics in Q4 2023 and has held it in 11 quarters since.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Oakworth Capital's 13F filing for Q2 2026, filed 22 Jul 2026.